AZ’ Calquence boosts PFS in CLL patients
The drug demonstrates “remarkable efficacy”, says AZ’ José Baselga
Read More
Tag: ELEVATE-TN
AZ’ Calquence shows PFS benefit in CLL patients
A new filing for the drug as a treatment for relapsed or refractory chronic lymphocytic leukaemia is expected later this year
Read More
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
